Thread by @MaxDelvallee

Pr @adarsh_bhimraj , in a recent @washingtonpost , you say a JAMA study showed ivermectin “did not help patients with mild covid-19”.

Here are the results of this study : HR 1.07, P=0.53. Does a p-value of 0.53 look statistically significant to you ?

washingtonpost.com/health/2021/04…

Also, what about the fact that the median age is 37 years old in the studied population, with patients recovering naturally very fast, and ivermectin still performs slightly better ?

Also, what do you think of the fact Ivermectin performs better in every single secondary outcome in this study, including death ? Funny for an ineffective drug, that a blinded RCT shows better symptom resolution despite of young age, right ?

Finally the article mentions you think this @JAMA_current study was “well-designed”.

What do you think about the fact the results were collected through phone survey, without physical examination ?

Thank you for your clarifications 🙂

Oh and one last thing : the participants in this study were eligible if they had not taken ivermectin 5 days before the study. Problem : ivermectin was widely used in Latin America at that time. Does the 5-days without IVM requirement sound enough to you?

nature.com/articles/d4158…